Top

Published in:

01-09-2010 | Original Paper

Standard PAH therapy improves long term survival in CTEPH patients

Authors: Hans-Juergen Seyfarth, Michael Halank, Heinrike Wilkens, Hans-Joachim Schäfers, Ralf Ewert, Martin Riedel, Ernst Schuster, Hans Pankau, Stefan Hammerschmidt, Hubert Wirtz

Published in: Clinical Research in Cardiology | Issue 9/2010

Abstract

Background

Chronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure.

Patients and methods

Fifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16–76 years; 36 female, 14 male). Kaplan–Meier plots of these patients were compared with Kaplan–Meier plots of two historical CTEPH patient groups without any specific vasodilative treatment by log rank tests.

Results

CTEPH patients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 ± 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p ≤ 0.0002).

Conclusion

Our data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH.

Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93:512–516PubMed

Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2599–2603CrossRefPubMed

Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ (2004) Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 23:595–600CrossRefPubMed

Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM (2006) Medical therapies for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3:594–600CrossRefPubMed

Dartevelle P, Fadel E, Mussot S, Chapelier A, Hervé P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G (2004) Chronic thromboembolic pulmonary hypertension. Eur Respir J 23:637–648CrossRefPubMed

Doyle RL, McC Douglas, Channick RN, Simmonneau G, Conte J (2004) Surgical treatments/interventions for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 126:63S–71SCrossRefPubMed

Egermayer P, Peacock AJ (2000) Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 15:440–448CrossRefPubMed

Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB (2007) Continous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 96:207–211CrossRef

Fedullo PF, Auger WR, Kerr KM, Rubin LJ (2001) Chronic thromboembolic pulmonary hypertension. N Engl J Med 345:1465–1472CrossRefPubMed

10.

Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F (2003) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139–1141CrossRefPubMed

11.

Hoeper MM, Kramm T, Wilkens H, Schulze C, Schaefers HJ, Welte T, Mayer E (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2363–2367CrossRefPubMed

12.

Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zaba J (2006) The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28:138–143CrossRefPubMed

13.

Jaïs X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, for the BENEFiT Study Group (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. JACC 52:2127–2134

14.

Mc Laughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, Rainisio M, Simonneau G, Rubin LJ (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244–249CrossRef

15.

Moser KM, Bloor CM (1993) Pulmonary vascular lesions occuring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103:685–692CrossRefPubMed

16.

Nagaya N, Shimizu Y, Satoh T, Oya H, Uematsu M, Kyotani S, Sakamaki F, Sato N, Nakanishi N, Miyatake K (2002) Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 87:340–345CrossRefPubMed

17.

Olschewski H, Hoeper MM, Borst MM, Ewert R, Grünig E, Kleber FX, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-Neick I, Wilkens H, Winkler J, Worth H (2007) Diagnosis and therapy of chronic pulmonary hypertension. Clin Res Cardiol 96:301–330CrossRefPubMed

18.

Olschewski H, Simonneau G, Galie N, Higgenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329CrossRefPubMed

19.

Ono F, Nagaya N, Okumura H, Shimizu Y, Kyotani S, Nakanishi N, Miyatake K (2003) Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 123:1583–1588CrossRefPubMed

20.

Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264CrossRefPubMed

21.

Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Chest 81:151–158CrossRefPubMed

22.

Rosenkranz S (2007) Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 96:527–541CrossRefPubMed

23.

Seyfarth HJ, Hammerschmidt S, Gessner C, Halank M, Wirtz H (2006) Chronic thromboembolic pulmonary hypertension—therapeutic options. Curr Respir Med Rev 2:431–438

24.

Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H (2006) Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 569:1–6

25.

Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J (2005) Bosentan improves exercise tolerance and Tei index in pulmonary hypertension patients with prostanoid therapy. Chest 128:709–713CrossRefPubMed

26.

Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie N, Humbert M, Rainisio M, Rubin LJ, Simonneau G (2005) Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60:1025–1030CrossRefPubMed

Title: Standard PAH therapy improves long term survival in CTEPH patients
Authors: Hans-Juergen Seyfarth
Michael Halank
Heinrike Wilkens
Hans-Joachim Schäfers
Ralf Ewert
Martin Riedel
Ernst Schuster
Hans Pankau
Stefan Hammerschmidt
Hubert Wirtz
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology / Issue 9/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-010-0156-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Standard PAH therapy improves long term survival in CTEPH patients

Abstract

Background

Patients and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2010

Right coronary artery chronic total occlusion revascularization by knuckle technique through right gastroepiploic artery graft

Trends in age-standardised and age-specific mortality from ischaemic heart disease in Germany

Isolated pulmonary vein tachycardia during atrial fibrillation

There are two sides to everything: two case reports on sequelae of rescue interventions to treat complications of transcatheter aortic valve implantation of the Medtronic CoreValve™ prosthesis

Time of admission, quality of PCI care, and outcome of patients with ST-elevation myocardial infarction

Cardiac tamponade following pericarditis 18 days after catheter ablation of atrial fibrillation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page